Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in Advanced NSCLC With Uncommon EGFR Mutations
NCT02961270Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Countries
- 1
- Sponsor
- Chinese Academy of Medical Sciences
- Modality
- Orthosteric Ligands
- Drugs
- icotinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 10 months. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Progression-Free Survival
Secondary
Objective Response Rate
Beyond the preview
Go deeper on NCT02961270.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961270.